Table 4.

Multi-omics studies focused on developing new therapeutic strategies for the treatment of BC.

Study	Omics Data	BC Subtype	Potential Targets
Iqbal et al. [59]	M+T	TNBC and luminal-like	CBX2 and CBX7
Gong et al. [69]	M+T	TNBC	FASN and LDH
Mahendralingam et al. [66]	P+T	Basal- and luminal-like	GLUT1, HK, LDH, and PDC
Putluri et al. [65]	M+T	Basal- and luminal-like	RRM2
Terunuma et al. [107]	M+T+P+E	TNBC and basal-like	ADHFE1
Hilvo et al. [60]	L+T	TNBC, luminal- and basal-like	ACACA, ELOVL1, FASN, INSIG1, SCAP, SCD and THRSP
Kang et al. [116]	L+T	Luminal-like	ELOVL2
Camarda et al. [102]	M+T	TNBC and HER2 +	CPT1 and CPT2

ACACA: acetyl-CoA carboxylase alpha, ADHFE1: alcohol dehydrogenase iron containing 1, CBX2: chromobox 2, CBX7: chromobox 7, CPT1: carnitine palmitoyltransferase 1A, CPT2: carnitine palmitoyltransferase 2, E: epigenomics, ELOVL1: ELOVL fatty acid elongase 1, ELOVL2: ELOVL fatty acid elongase 2, FASN: fatty acid synthase, GLUT1: glucose transporter 1, HK: hexokinase, IDH2: isocitrate dehydrogenase (NADP(+)) 2, INSIG1: insulin-induced gene 1, L: lipidomics, LDH: lactate dehydrogenase, M: metabolomics, P: proteomics, PDC: pyruvate dehydrogenase kinase, RRM2: ribonucleotide reductase regulatory subunit M2, SCAP: SREBF chaperone, SCD: stearoyl-CoA desaturase, T: transcriptomics, TNBC: triple negative breast cancer, THRSP: thyroid hormone-responsive.